Introduction: The Intersection of Hematology and Reproductive Health
For decades, the clinical management of sickle cell disease (SCD) focused primarily on the prevention and treatment of vaso-occlusive crises (VOC), acute chest syndrome, and stroke. However, as medical advancements have extended the life expectancy of individuals with SCD, the nuances of chronic disease management—particularly regarding reproductive health—have come to the forefront. For female patients, the menstrual cycle is not merely a physiological process but a potential trigger for acute complications. Despite this, the interplay between menstruation and SCD remains one of the most understudied areas in hematology.
Menstruation in the context of SCD is uniquely complex. These patients often face a triad of challenges: delayed puberty, early menopause, and abnormal uterine bleeding (AUB). Furthermore, the physiological changes during the menstrual cycle, including prostaglandin release and hormonal fluctuations, can exacerbate SCD-related pain, leading to a phenomenon where menstruation-related cramping and systemic sickle cell pain overlap. A recent multicenter study published in JAMA Network Open provides a critical look at this intersection, highlighting the urgent need for integrated reproductive health assessments within sickle cell clinics.
Study Overview and Methodology
The study, titled Role of Menstrual Bleeding Assessments in Sickle Cell Clinics, was a cross-sectional survey conducted across 13 outpatient SCD centers in the United States between March 2022 and May 2024. The research team, led by Rush et al., sought to quantify menstrual patterns, assess access to contraceptive therapy, and evaluate clinician practices in the context of reproductive health for female patients with SCD.
Participant Demographics and Data Collection
The study enrolled 211 female participants with a mean age of 23.7 years. Eligibility criteria included having reached menarche at least 12 months prior to enrollment and not being currently pregnant or postmenopausal. To ensure a comprehensive view, the study utilized a dual-survey approach:
1. Patient-Facing Surveys: Used age-appropriate menstrual bleeding questionnaires and the Patient-Reported Outcomes Measurement Information System (PROMIS) scales to evaluate mental and physical health. These surveys specifically queried SCD-related pain during menses and current contraceptive use.
2. Clinician-Facing Surveys: Surveyed the hematologists and healthcare providers treating the participants. Clinicians reviewed the patient’s survey responses and then reported on the patient’s clinical history and intended future care plans.
This methodology allowed researchers to bridge the gap between patient experience and clinical awareness, providing a clear picture of how menstrual health impacts broader SCD outcomes.
Key Findings: The Burden of Menstrual Pain and AUB
The results of the study underscore a significant and often overlooked burden of disease. Abnormal uterine bleeding and menstruation-triggered sickle cell pain were not only common but were directly correlated with increased utilization of emergency and inpatient services.
Abnormal Uterine Bleeding and Hospitalization
Of the 211 participants, 24.6% (52 individuals) were identified as having abnormal uterine bleeding. The clinical implications of AUB in this population are profound. The study found that 59.1% of the AUB group had been hospitalized in the preceding period, compared to only 34.5% of those without AUB. This suggests that AUB may be a marker for increased disease severity or a direct contributor to the physiological stress that triggers VOC.
The Cycle of Pain
One of the most striking findings was the prevalence of sickle cell pain associated with menses. Nearly two-thirds of the participants (64.4%) reported experiencing SCD-related pain during their menstrual cycles. This pain was not merely dysmenorrhea but was identified by patients as being distinctively related to their SCD. The frequency of emergency department (ED) visits was significantly higher in this group:
– 19.1% of patients with menstrual-associated SCD pain had four or more ED visits in the six months prior to enrollment.
– In contrast, only 4.6% of patients without menstrual-associated pain had a similar frequency of ED visits.
A similar trend was seen in hospitalizations. Among those endorsing sickle cell pain with menses, 8.7% had four or more hospitalizations, compared to just 1.5% in the non-pain group. These data suggest that for a majority of female patients, the monthly cycle is a period of high risk for acute medical crises.
The Contraceptive Paradox: Low Utilization and High Need
Despite the clear link between menstruation and SCD complications, the study revealed a startling lack of intervention. Hormonal contraception, which can effectively manage AUB and reduce the frequency of menstrual cycles (and thus potentially reduce cycle-triggered pain), was significantly underutilized.
Only 19.2% of participants reported using hormonal contraception. Perhaps more concerning was the lack of education: 22.1% of participants stated they had never even heard of these medications as a potential management tool for their symptoms. This highlights a systemic failure in providing comprehensive reproductive health education to young women with SCD.
Clinician Response and the Path to Integrated Care
The study did not just identify problems; it also demonstrated that simple screening tools can change clinical behavior. After clinicians reviewed the patient-facing surveys, their intended management plans shifted significantly. Clinicians reported several immediate steps to improve care:
– 72.4% planned to provide reproductive health education.
– 49.7% intended to refer the patient to a reproductive health specialist (OB/GYN).
– 16.0% initiated a workup for iron deficiency, which is often exacerbated by AUB.
– 11.6% planned to investigate underlying bleeding disorders.
Notably, three of the participating sites were motivated to establish new multidisciplinary clinics that co-locate hematology and reproductive health services. This move toward integrated care is essential for addressing the multifaceted needs of this patient population.
Expert Commentary: Mechanistic Insights and Clinical Implications
From a physiological standpoint, the link between menstruation and sickle cell crises is highly plausible. During the late luteal phase and the onset of menses, there is a surge in inflammatory cytokines and prostaglandins. Prostaglandins cause uterine smooth muscle contraction but also promote systemic inflammation and vasoconstriction. In a patient with SCD, these factors can exacerbate the sickling process and promote vaso-occlusion in the microvasculature. Furthermore, the blood loss associated with AUB can worsen the chronic anemia inherent to SCD, leading to increased fatigue and a lower threshold for pain.
However, there has historically been a “silo effect” in medicine where hematologists manage the blood and OB/GYNs manage the reproductive organs, with little communication between the two. This study proves that when hematologists are prompted to ask about menstrual health, they discover significant unmet needs. The use of a simple, brief assessment tool can bridge this gap, ensuring that menstrual cycles are treated as a vital sign in the management of SCD.
Study Limitations and Future Research
While the study provides robust multicenter data, there are limitations to consider. The cross-sectional nature of the survey means that it can identify associations but not definitively prove causation. Additionally, the study relied on patient self-reporting for ED visits and hospitalizations, which may be subject to recall bias. Future longitudinal studies are needed to determine if the initiation of hormonal contraception or the establishment of multidisciplinary clinics leads to a measurable decrease in VOC frequency and improved quality of life.
Conclusion: A Call to Action for Clinicians
The findings by Rush et al. serve as a clarion call for sickle cell clinicians. Menstrual health is not a peripheral issue; it is a central driver of acute care utilization and patient morbidity. To improve the standard of care, SCD clinics must:
1. Implement Routine Screening: Use brief, validated questionnaires to assess menstrual patterns and pain during every clinic visit.
2. Prioritize Education: Proactively discuss the benefits and risks of hormonal contraception, not just for birth control, but as a therapeutic tool for disease management.
3. Foster Interdisciplinary Collaboration: Build strong referral pathways or co-located clinics with OB/GYN specialists who are familiar with the unique needs of patients with hemoglobinopathies.
By integrating reproductive health into the standard of SCD care, we can move closer to a truly holistic approach that recognizes and addresses the unique challenges faced by female patients, ultimately reducing the burden of pain and hospitalizations.
References
1. Rush G, Mohamed RE, Moffatt-Bazile K, et al. Role of Menstrual Bleeding Assessments in Sickle Cell Clinics. JAMA Netw Open. 2025;8(12):e2546345. doi:10.1001/jamanetworkopen.2025.46345.
2. Smith-Whitley K. Reproductive health in girls and women with sickle cell disease. Hematology Am Soc Hematol Educ Program. 2014;2014(1):489-495.
3. Osunkwo I, O’Connor S, Saidi E. Management of the reproductive health of the female patient with sickle cell disease. J Community Hosp Intern Med Perspect. 2015;5(5):28751.
